Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

LineMatrix® Biological Vascular Graft for Infra-renal Arterial Bypass or Replacement

NCT: NCT07733076 · NOT_YET_RECRUITING

NCT IDNCT07733076
StatusNOT_YET_RECRUITING
Start Date2026-09-30
Completion2028-09-30
SponsorShanghai Zhongshan Hospital (OTHER)
First posted
Last updated

Brief Summary

Single center, single arm study to evaluate the Safety and Efficacy of LineMatrix® Biological Vascular Graft for Infra-renal Arterial Bypass or Replacement

Frequently Asked Questions

What is LineMatrix® Biological Vascular Graft for Infra-renal Arterial Bypass or Replacement?

LineMatrix® Biological Vascular Graft for Infra-renal Arterial Bypass or Replacement is a clinical trial registered under NCT07733076. Current status: NOT_YET_RECRUITING.

What is the status of NCT07733076?

The current status of NCT07733076 (LineMatrix® Biological Vascular Graft for Infra-renal Arterial Bypass or Replacement) is: NOT_YET_RECRUITING.

When did LineMatrix® Biological Vascular Graft for Infra-renal Arterial Bypass or Replacement start?

LineMatrix® Biological Vascular Graft for Infra-renal Arterial Bypass or Replacement started on 2026-09-30.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑